Update on trading and COVID-19 related manufacturing contract
Download the full announcement
Further increase in expected orders for PrimeStore MTM sample collection devices
Orders received for the two months ending July totalling $9.4m
EKF Diagnostics Holdings plc (AIM: EKF), the AIM quoted point-of-care business, provides an update on the further increase in manufacturing demand from Longhorn Vaccines and Diagnostics LLC (“Longhorn”) in the US, for their FDA-approved PrimeStore MTM sample collection device, which deactivates viruses, bacteria, fungi and mycobacterium tuberculosis allowing safe sample handling and transport, greatly reducing risk of infection.
The Company announced on 27 April 2020 that it expected further orders worth over $3m for May and that it was in the process of doubling capacity at its Boerne, Texas site for the reagent used in the manufacture of the Primestore MTM device, in order to fulfil those orders and anticipated additional future orders. EKF now confirms that it has received further orders from Longhorn totalling $9.4m for the two months ending July. The majority of these further orders will be for the same core reagent manufactured by EKF.
The additional contribution now indicated for June under the Longhorn manufacturing contract means that the Company expects to further exceed the overall management budgets for H1 2020 more confidently than was noted on 27 April. EKF now expects to deliver Group revenues of at least £25m for the six months ended 30 June 2020 (H1 2019: £21.44m) and adjusted EBITDA of at least £7.5m, a 34% increase on the same period last year (H1 2019: £5.58m).
EKF is substantially increasing its manufacturing capacity to meet the demand for the Primestore MTM Device. The Company’s facility in Wales is now operational and shipped its first product this week and EKF has begun the process to start manufacturing in Germany. The Company also expects to expand capacity in the United States in the very near future due to an acceleration in its capital expenditure programme.
Sadly, the pandemic is still gaining momentum in most areas of the United States. The US Administration is emphasizing testing as the most appropriate means to contain the virus. In these circumstances, the Board expects the second half of the year will see continued momentum and the full year results will exceed, perhaps considerably, its recently upgraded expectations.
EKF Diagnostics Holdings plc
Tel: 00 44 29 2071 0570
|N+1 Singer (Nomad & Broker)
Aubrey Powell / Lauren Kettle / George Tzimas (Corporate Finance)Tom Salvesen (Corporate Broking)
|Tel: 020 7496 3000|
Walbrook PR Limited
|Tel: 020 7933 8780 or
Mob: 07980 541 893 / 07584 391 303